Skip to content

19-255 - Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Status: open

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti–PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

Treatment for Cervical Cancer

Contact Us Or call (251) 445-9834

Description

This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy. The study is not intended to compare the efficacy of the 2 experimental arms. Rather, the efficacy of each arm will be evaluated against its relevant historical controls as appropriate.

Sponsors

This trial is sponsored by Incyte Corporation.

Principle Investigator

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.